Ambrosia Biosciences announces $16MM Series A FinancingBOULDER, Colo., August 20, 2024-- Ambrosia Biosciences Inc ('Ambrosia' or 'the Company'), today announced the successful first closing of its Series A financing. The financing totaled $16 million, and was led by BVF Partners and Boulder Ventures.

Ambrosia Biosciences宣布A系列融资1600万美元，科罗拉多州博尔德，2024年8月20日——Ambrosia Biosciences Inc（“Ambrosia”或“公司”）今天宣布其A系列融资首次成功结束。融资总额为1600万美元，由BVF Partners和Boulder Ventures牵头。

Ambrosia's financing will be used to scale up its drug discovery programs and laboratory operations in Boulder, CO..

安布罗西亚的资金将用于扩大其在博尔德（Boulder，CO.）的药物发现计划和实验室运营。

'Array BioPharma was among the best small molecule drug discovery teams on the planet,' said Kyle Lefkoff, Founding Partner at Boulder Ventures and Executive Chairman of Ambrosia. 'With the recent shut down of the Pfizer/Array R&D facility here in Boulder, we have re-assembled the Array medicinal chemistry team at Ambrosia to apply that same expertise to obesity.'.

随着辉瑞/阵列研发设施最近在博尔德的关闭，我们在安布罗西亚重新组建了阵列药物化学团队，将同样的专业知识应用于肥胖症。”

The Company will initially discover and develop novel orally delivered, small molecule-based therapies targeting incretins and other class B GPCRs. Nick Traggis, President and Founder of Ambrosia, added, 'While this is a very active space, there is significant science yet to be understood and plenty of opportunity to improve upon existing GLP-1 based drugs.

该公司最初将发现并开发针对肠促胰岛素和其他B类GPCR的新型口服小分子疗法。Ambrosia总裁兼创始人尼克·特拉吉斯（NickTraggis）补充道，“虽然这是一个非常活跃的领域，但仍有重要的科学有待理解，还有很多机会改进现有的基于GLP-1的药物。

I'm proud of the work our founding science team has already done and look forward to using this financing to scale up our drug discovery efforts.'.

我为我们的创始科学团队所做的工作感到骄傲，并期待着利用这笔资金扩大我们的药物发现工作。”

About Ambrosia Biosciences Inc.

关于Ambrosia Biosciences Inc。

Ambrosia Biosciences Inc. is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders. For more information, please visit www.ambrosiabiosciences.comContact:

Ambrosia Biosciences Inc.是一家私营药物发现公司，开发口服小分子疗法治疗肥胖症和其他代谢紊乱。有关更多信息，请访问www.ambrosiabiosciences.com联系方式：

Media Contact

媒体联系人

(720) 841 - 3816

(720) 841 - 3816

PR@ambrosia.health

PR@ambrosia.health